eligibility_summary
Adults 18–75 with recurrent/metastatic NPC not curable by surgery/RT, progressed after 1st-line platinum, ECOG 0–1, ≥3‑month life expectancy, measurable disease, adequate organ function, consent. Exclude: severe allergy, prior anti‑EGFR/PD‑1, other cancers, recent major CV events, trials, surgery, live vaccines, or immunosuppression, active autoimmune disease (controlled T1DM/hypothyroid/skin ok), active TB/HBV/HCV/HIV (HBsAg low DNA or HCV RNA− allowed), ILD/pneumonitis, serious comorbidity/psych/substance issues, immunodeficiency, pregnancy/lactation, refuse contraception, surgical candidates.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06259721: Single-arm Phase II in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma testing triple therapy: 1) Anti-PD‑1 monoclonal antibody (checkpoint inhibitor, e.g., toripalimab, camrelizumab, tislelizumab) blocking the PD‑1/PD‑L1 axis to restore cytotoxic T‑cell activity, 2) Nimotuzumab (IgG1 anti‑EGFR monoclonal antibody) inhibiting EGFR signaling and inducing antibody‑dependent cellular cytotoxicity (ADCC), 3) Capecitabine (oral fluoropyrimidine prodrug of 5‑FU, antimetabolite) converted to 5‑FU to inhibit thymidylate synthase and DNA synthesis. Targeted cells/pathways: exhausted CD8+ T cells via PD‑1, EGFR pathway on NPC tumor cells, innate effectors (NK cells via ADCC), dendritic cell–T‑cell crosstalk/antigen presentation, and proliferating tumor cells via thymidylate synthase inhibition.